Recordati【REC】銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

58.75

買値

58.50

売値

59.25

出来高

217,202

58.55 日の範囲 59.20

47.28 52 週間の範囲 59.20

時価総額

12.065B

前日終値

59.00

始値

59.20

時刻

1033

58.75

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

291,672

発行済株式数

205,358,104

配当利回り

2.09%

PER

29.30

1 株当たり利益 (EPS)

1.9

歳入

2.07B

純利益

389.21M

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.recordati.it

本社

Milan, Lombardy, Ita

設立

1926

Recordati SpA is listed in the Pharmaceutical Preparations sector of the イタリア証券取引所 with ticker REC. The last closing price for Recordati was 59.00 €. Over the last year, Recordati shares have traded in a share price range of 47.28 € to 59.20 €.

Recordati currently has 205,358,104 shares in issue. The market capitalisation of Recordati is 12.12 € billion. Recordati has a price to earnings ratio (PE ratio) of 29.30.

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5% Consolidated net revenue of € 1,743.1 million in the...

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi...

Recordati Rare Diseases annonce la publication dans The Journal of Clinical Endocrinology & Metabolism des résultats de l’étude de Phase III LINC 4 confirmant l'efficacité et la tolérance d’Isturisa® (osilodrostat)...

L’étude LINC 4 a démontré la supériorité d’Isturisa® (osilodrostat) comparé au placebo pour normaliser le cortisol au cours de la phase de 12 semaines en double aveugle, randomisée de l’étude (77...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER...

Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study Presented Today at the Endocrine Society’s Annual...

Statistically significant results from the pivotal Phase III LINC 4 study demonstrate that Isturisa® (osilodrostat) provides rapid and sustained normalisation of mean urinary free cortisol levels...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	2.85	5.09838998211	55.9	59.2	55.75	359953	57.16229458	DE
4	7	13.5265700483	51.75	59.2	51.15	298315	54.92140127	DE
12	6.7	12.8722382325	52.05	59.2	48.58	291672	52.54379104	DE
26	9.09	18.3044703987	49.66	59.2	47.98	257272	52.04735014	DE
52	7.97	15.6951555731	50.78	59.2	47.28	243359	51.24001394	DE
156	8.9	17.853560682	49.85	59.2	34.52	237043	45.74625495	DE
260	18.91	47.4648594378	39.84	59.2	28.26	280627	45.27450499	DE

REC - Frequently Asked Questions (FAQ)

What is the current Recordati share price?

The current share price of Recordati is 58.75 €

How many Recordati shares are in issue?

Recordati has 205,358,104 shares in issue

What is the market cap of Recordati?

The market capitalisation of Recordati is EUR 12.12B

What is the 1 year trading range for Recordati share price?

Recordati has traded in the range of 47.28 € to 59.20 € during the past year

What is the PE ratio of Recordati?

The price to earnings ratio of Recordati is 29.3

What is the cash to sales ratio of Recordati?

The cash to sales ratio of Recordati is 5.52

What is the reporting currency for Recordati?

Recordati reports financial results in EUR

What is the latest annual turnover for Recordati?

The latest annual turnover of Recordati is EUR 2.07B

What is the latest annual profit for Recordati?

The latest annual profit of Recordati is EUR 389.21M

What is the registered address of Recordati?

The registered address for Recordati is VIA MATTEO CIVITALI 1, MILAN, LOMBARDY, 20148

What is the Recordati website address?

The website address for Recordati is www.recordati.it

Which industry sector does Recordati operate in?

Recordati operates in the PHARMACEUTICAL PREPARATIONS sector

銘柄コード	株価	出来高
WABTGAlfio Bardolla Training Group Spa	0.15 € (25.00%)	1.35k
EPHEPH SpA	0.021 € (23.53%)	144.59k
NTWNetweek SpA	0.069 € (21.05%)	6.56M
1SPCEVirgin Galactic Holdings Inc	5.30 € (15.22%)	600
MPTImpianti SpA	0.276 € (15.00%)	160.5k
WERFOLaboratorio Farmaceutico Erfo SPA	0.0212 € (-29.33%)	5.56k
OSAOSAI Automation System SpA	0.304 € (-18.93%)	449.42k
1WBAWalgreens Boots Alliance Inc	9.466 € (-13.32%)	516
SOGESASoges Group AA	0.0098 € (-10.91%)	3.9k
WS3D25Solid World Group spa	0.182 € (-9.00%)	67.8k
TITTelecom Italia SpA	0.2655 € (-0.45%)	82.64M
SPMSaipem Spa	2.365 € (0.72%)	22.21M
BMPSBanca Monte Dei Paschi Di Siena Spa	6.198 € (-0.48%)	20.74M
ISPIntesa Sanpaolo Spa	4.1935 € (-0.57%)	18.17M
TITRTelecom Italia	0.3079 € (-0.52%)	15.89M

銘柄コード

株価

出来高

TITTelecom Italia SpA

0.2655 €

(-0.45%)

82.64M

SPMSaipem Spa

2.365 €

(0.72%)

22.21M

BMPSBanca Monte Dei Paschi Di Siena Spa

6.198 €

(-0.48%)

20.74M

ISPIntesa Sanpaolo Spa

4.1935 €

(-0.57%)

18.17M

TITRTelecom Italia

0.3079 €

(-0.52%)

15.89M

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Recordati SpA (REC)

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

Recordati SpA について

REC 最新ニュース

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases annonce la publication dans The Journal of Clinical Endocrinology & Metabolism des résultats de l’étude de Phase III LINC 4 confirmant l'efficacité et la tolérance d’Isturisa® (osilodrostat)...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study Presented Today at the Endocrine Society’s Annual...

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Recordati SpA (REC) 銘柄情報

Recordati SpA (REC)

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

Recordati SpA について

REC 最新ニュース

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases annonce la publication dans The Journal of Clinical Endocrinology & Metabolism des résultats de l’étude de Phase III LINC 4 confirmant l'efficacité et la tolérance d’Isturisa® (osilodrostat)...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study Presented Today at the Endocrine Society’s Annual...

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

広告を削除する